Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies

Journal of Virology

Volumn 74, Issue 9, 2000, Pages 4236-4243

  Stittelaar, Koert J ^a,b   Wyatt, Linda S ^c   De Swart, Rik L ^a   Vos, Helma W ^a   Groen, Jan ^a   Van Amerongen, Geert ^b   Van Binnendijk, Robert S ^b   Rozenblatt, Shmuel ^c,d   Moss, Bernard ^c   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; HOST RESISTANCE; IMMUNE RESPONSE; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HEMAGGLUTININS, VIRAL; MACACA FASCICULARIS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

EID: 0034002502     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.9.4236-4243.2000     Document Type: Article

References (29)

1. Auwaerter, P. G., P. A. Rota, W. R. Elkins, R. J. Adams, T. DeLozier, Y. Shi, W. J. Bellini, B. R. Murphy, and D. E. Griffin. 1999. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J. Infect. Dis. 180:950-958.
2. Clements, C. J., and F. T. Cutts. 1995. The epidemiology of measles: thirty years of vaccination. Curr. Top. Microhiol. Immunol. 191:13-33.
3. Cutts, F. T., and L. E. Markowitz. 1994. Successes and failures in measles control. J. Infect. Dis. 170(Suppl. 1):S32-S41.
4. De Swart, R. L., H. W. Vos, F. G. C. M. UytdeHaag, A. D. M. E. Osterhaus, and R. S. Van Binnendijk. 1998. Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies in a FACS-measured immunofluorescence assay. J. Virol. Methods 71:35-44.
5. Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 1998. Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.19. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Greene Publishing Associates & Wiley Interscience, New York, N. Y.
6. Forsey, T., A. B. Heath, and P. D. Minor. 1991. The 1st International Standard for anti-measles serum. Biologicals 19:237-241.
7. Fulginiti, V. A., J. J. Eller, A. W. Downte, and C. H. Kempe. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated virus vaccines. JAMA 202:101-106.
8. Griffin, D. E., and W. J. Bellini. 1996. Measles virus, p. 1267-1312. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
9. Harris, R. W., P. Isacson, and D. T. Karzon. 1969. Vaccine-induced hypersensitivity: reactions to live measles and mumps vaccine in prior recipients of inactivated measles vaccine. J. Pediatr. 74:552-563.
10. Helfand, R. F., D. K. Kim, H. E. J. Gary, G. L. Edwards, G. P. Bisson, M. J. Papania, J. L. Heath, D. L. Schaff, W. J. Bellini, S. C. Redd, and L. J. Anderson. 1998. Nonclassic measles infections in an immune population exposed to measles during a college bus trip. J. Med. Virol. 56:337-341.
11. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
12. Luttmann, W., B. Knoechel, M. Foerster, H. Matthys, J. C. Virchow, Jr., and C. Kroegel. 1996. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J. Immunol. 157:1678-1683.
13. Mackett, M., G. L. Smith, and B. Moss. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
14. McNair, T. F., and D. E. Bonanno. 1967. Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine. N. Engl. J. Med. 5:248-251.
15. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
16. Osterhaus, A., G. Van Amerongen, and R. van Binnendijk. 1998. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine 16:1479-1481.
17. Osterhaus, A. D. M. E., P. De Vries, and R. S. Van Binnendijk. 1994. Measles vaccines: novel generations and new strategies. J. Infect. Dis. 170(Suppl. 1):S42-S55.
18. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634.
19. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
20. Rosel, J. L., P. L. Earl, J. P. Weir, and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindlII H genome fragment. J. Virol. 60:436-449.
21. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
22. Stern, L. B.-L., M. Greenberg, J. M. Gershoni, and S. Rozenblatt. 1995. The hemagglutinin envelope protein of canine distemper virus (CDV) confers cell tropism as illustrated by CDV and measles virus complementation analysis. J. Virol. 69:1661-1668.
23. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schäfer, and A. Holzner. 1974. MVA-Stufenimpfung gegen Pocken. Klinische Erprobung des attenuierten Pocken-Lebenimpfstoffes, Stamm MVA. Dtsch. Med. Wochenschr. 99:2386-2392.
24. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
25. Sutler, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040.
26. Van Binnendijk, R. S., M. C. M. Poelen, G. Van Amerongen, P. De Vries, and A. D. M. E. Osterhaus. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524-534.
27. Van Binnendijk, R. S., R. W. J. van der Heijden, G. Van Amerongen, F. G. C. M. UytdeHaag, and A. D. M. E. Osterhaus. 1994. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J. Infect. Dis. 170:443-448.
28. Wild, T. F. 1999. Measles vaccines, new developments and immunization strategies. Vaccine 17:1726-1729.
29. Wyatt, L. S., S. T. Shors, B. R. Murphy, and B. Moss. 1996. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458.